Gain insights on the performance of Inotiv’s R2G2 mouse model with our white paper. This paper provides data on overall survival rate and animal body weights – two important variables in preclinical oncology pharmaceutical studies.
Make the most optimal choice for preclinical testing of your investigational cancer therapy by learning about how the R2G2 mouse. This model performed in terms of tolerating chemotherapy drugs, maintaining a stable weight, and exhibiting adverse effects in response to estrogen therapy.
Download today to explore:
- The background of the R2G2® mouse
- How the R2G2® mouse generally handled three standard-of-care chemotherapy drugs in terms of overall survival and body weight
- Adverse effects to estrogen therapy in the R2G2® mouse in terms of survival and body weight
